{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:32:12Z","timestamp":1787016732452,"version":"build-2736575974"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    DC-159a is a new 8-methoxy fluoroquinolone that possesses a broad spectrum of antibacterial activity, with extended activity against gram-positive pathogens, especially streptococci and staphylococci from patients with community-acquired infections. DC-159a showed activity against\n                    <jats:italic>Streptococcus<\/jats:italic>\n                    spp. (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , 0.12 \u03bcg\/ml) and inhibited the growth of 90% of levofloxacin-intermediate and -resistant strains at 1 \u03bcg\/ml. The MIC\n                    <jats:sub>90<\/jats:sub>\n                    s of DC-159a against\n                    <jats:italic>Staphylococcus<\/jats:italic>\n                    spp. were 0.5 \u03bcg\/ml or less. Against quinolone- and methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    strains, however, the MIC\n                    <jats:sub>90<\/jats:sub>\n                    of DC-159a was 8 \u03bcg\/ml. DC-159a was the most active against\n                    <jats:italic>Enterococcus<\/jats:italic>\n                    spp. (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , 4 to 8 \u03bcg\/ml) and was more active than the marketed fluoroquinolones, such as levofloxacin, ciprofloxacin, and moxifloxacin. The MIC\n                    <jats:sub>90<\/jats:sub>\n                    s of DC-159a against\n                    <jats:italic>Haemophilus influenzae, Moraxella catarrhalis<\/jats:italic>\n                    , and\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    were 0.015, 0.06, and 0.25 \u03bcg\/ml, respectively. The activity of DC-159a against\n                    <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n                    was eightfold more potent than that of levofloxacin. The MICs of DC-159a against\n                    <jats:italic>Chlamydophila pneumoniae<\/jats:italic>\n                    were comparable to those of moxifloxacin, and DC-159a was more potent than levofloxacin. The MIC\n                    <jats:sub>90<\/jats:sub>\n                    s of DC-159a against\n                    <jats:italic>Peptostreptococcus<\/jats:italic>\n                    spp.,\n                    <jats:italic>Clostridium difficile<\/jats:italic>\n                    , and\n                    <jats:italic>Bacteroides fragilis<\/jats:italic>\n                    were 0.5, 4, and 2 \u03bcg\/ml, respectively; and among the quinolones tested it showed the highest level of activity against anaerobic organisms. DC-159a demonstrated rapid bactericidal activity against quinolone-resistant\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    strains both in vitro and in vivo. In vitro, DC-159a showed faster killing than moxifloxacin and garenoxacin. The bactericidal activity of DC-159a in a murine muscle infection model was revealed to be superior to that of moxifloxacin. These activities carried over to the in vivo efficacy in the murine pneumonia model, in which treatment with DC-159a led to bactericidal activity superior to those of the other agents tested.\n                  <\/jats:p>","DOI":"10.1128\/aac.00853-07","type":"journal-article","created":{"date-parts":[[2007,10,15]],"date-time":"2007-10-15T20:34:15Z","timestamp":1192480455000},"page":"65-76","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":57,"title":["In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone"],"prefix":"10.1128","volume":"52","author":[{"given":"Kazuki","family":"Hoshino","sequence":"first","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Inoue","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kurosaka","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Namba","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kashimoto","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Uoyama","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Okumura","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saito","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Otani","sequence":"additional","affiliation":[{"name":"Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2003.00559.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3049-3054.2000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.6.1279"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043252"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/430829"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-005-0059-x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg320"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1086\/505117","volume":"43","year":"2006","unstructured":"Greene, C. M., M. H. Kyaw, S. M. Ray, W. Schaffner, R. Lynfield, N. L. Barrett, C. Long, K. Gershman, T. Pilishvili, A. Roberson, E. R. Zell, C. G. Whitney, and N. M. Bennett. 2006. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin. Infect. Dis.43:141-150.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_10_2","unstructured":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. 2006"},{"key":"e_1_3_2_11_2","first-page":"308","volume":"40","year":"1992","unstructured":"Japan Society of Chemotherapy. 1992. Method for in vitro determination of chlamydial susceptibility\u2014standard method of Japanese Society of Chemotherapy. Chemotherapy40:308-314.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_12_2","first-page":"76","volume":"29","year":"1981","unstructured":"Japan Society of Chemotherapy. 1981. Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by agar dilution method. Chemotherapy29:76-79.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.5.1193-1197.2005"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.2.221"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2003.51501.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051642"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1209.060397"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0907.020589"},{"key":"e_1_3_2_19_2","unstructured":"Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement. 2005"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3750-3759.2003"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/496986"},{"key":"e_1_3_2_22_2","first-page":"718","volume":"32","year":"1984","unstructured":"Sawatari, K., N. Ito, M. Nagasawa, H. Nakasato, H. Koga, K. Watanabe, et al. 1984. New susceptibility testing medium (B-SYE agar) for Legionella and Legionella-like organisms. Chemotherapy32:718-723.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki315"},{"key":"e_1_3_2_24_2","first-page":"32","volume":"24","year":"2004","unstructured":"Shopsin, B., X. Zhao, B. N. Kreiswirth, G. S. Tillotson, and K. Drlica. 2004. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int. J. Antimicrob. Agents24:32-34.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3630-3635.2004"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1520"},{"key":"e_1_3_2_27_2","first-page":"972","volume":"1","year":"2003","unstructured":"Waites, K. B., Y. Rikihisa, and D. T. Robinson. 2003. Mycoplasma and Ureaplasma, p. 972-990. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology,vol. 1, 8th ed. ASM Press, Washington, DC.","journal-title":"Manual of clinical microbiology"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0911.030284"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3517-3523.2001"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.02.009"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3311-3315.2002"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00151829-200605060-00009"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00853-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00853-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:30:51Z","timestamp":1645453851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00853-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1128\/AAC.00853-07"],"URL":"https:\/\/doi.org\/10.1128\/aac.00853-07","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"2007-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}